Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma.

ABSTRACT: Liver cancer is the fourth most common cause of cancer-related death worldwide, with hepatocellular carcinoma (HCC) being the main primary malignancy affecting the liver. Unfortunately, there are still limited therapeutic options for HCC, and even the latest advances have only increased the overall survival modestly. Thus, new treatment strategies and rational drug combinations are urgently needed. Reactivation of receptor tyrosine kinases (RTK) has been described as a mechanism of intrinsic resistance to targeted therapies in a variety of cancers, including inhibitors of mTOR. The design of rational combination therapies to overcome this type of resistance is complicated by the notion that multiple RTK can be upregulated during the acquisition of resistance. SHP2, encoded by the gene PTPN

SUBMITTER: Mulero-Sanchez A 

PROVIDER: S-EPMC10257427 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature